Get the Stockscreener App
6.45
2.86%
-0.19
After Hours:
6.46
0.010
+0.16%
Karyopharm Therapeutics Inc stock is traded at $6.45, with a volume of 65,889.
It is down -2.86% in the last 24 hours and up +60.45% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$6.64
Open:
$6.66
24h Volume:
65,889
Relative Volume:
0.44
Market Cap:
$55.93M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.589
EPS:
-10.95
Net Cash Flow:
$-102.89M
1W Performance:
-2.27%
1M Performance:
+60.45%
6M Performance:
-14.34%
1Y Performance:
-41.56%
1-Day Range:
$6.39
$6.85
1-Week Range:
$5.70
$6.89
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.45 | 53.85M | 137.27M | -123.57M | -102.89M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics Board Member Resigns Amid Career Shift - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65% - simplywall.st
Karyopharm concludes enrolment in Phase III myelofibrosis treatment trial - Yahoo Finance
Karyopharm completes enrollment in phase 3 myelofibrosis trial - Investing.com India
Karyopharm completes enrollment in phase 3 myelofibrosis trial By Investing.com - Investing.com Nigeria
Karyopharm announces completion of enrollment in the phase 3 SENTRY trial in myelofibrosis - MarketScreener
Karyopharm Therapeutics Inc. Announces Completion of Enrollment in the Phase 3 Sentry Trial in Myelofibrosis - MarketScreener
Adage Capital Partners GP L.L.C. Sells 5,898,520 Shares of Karyopharm Therapeutics Inc. $KPTI - MarketBeat
Published on: 2025-09-08 20:44:00 - beatles.ru
Karyopharm Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsWatch List & Technical Analysis for Trade Confirmation - beatles.ru
Palo Alto Investors LP Cuts Stock Holdings in Karyopharm Therapeutics Inc. $KPTI - MarketBeat
Birchview Capital LP Trims Holdings in Karyopharm Therapeutics Inc. $KPTI - MarketBeat
Is Karyopharm Therapeutics Inc. gaining market share2025 Earnings Surprises & Technical Analysis for Trade Confirmation - classian.co.kr
Analyzing recovery setups for Karyopharm Therapeutics Inc. investorsJuly 2025 Rallies & Verified Momentum Stock Ideas - Newser
Multi factor analysis applied to Karyopharm Therapeutics Inc.2025 Support & Resistance & Daily Profit Maximizing Trade Tips - Newser
Will Karyopharm Therapeutics Inc. benefit from current market trendsMarket Weekly Review & Daily Stock Trend Reports - خودرو بانک
Can Karyopharm Therapeutics Inc. recover in the next quarterJuly 2025 Final Week & Daily Profit Focused Stock Screening - Newser
Is Karyopharm Therapeutics Inc. benefiting from innovation trendsJuly 2025 Trends & Free Community Supported Trade Ideas - خودرو بانک
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Karyopharm Therapeutics Inc. stock daily chart insights2025 Retail Activity & Low Drawdown Trading Techniques - Newser
What are Karyopharm Therapeutics Inc.’s recent SEC filings showingWeekly Profit Summary & AI Based Buy and Sell Signals - خودرو بانک
Is Karyopharm Therapeutics Inc. trending in predictive chart modelsMarket Risk Report & Fast Moving Stock Watchlists - Newser
What candlestick patterns are forming on Karyopharm Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Alerts - Newser
Using data tools to time your Karyopharm Therapeutics Inc. exitJuly 2025 Setups & Weekly Watchlist for Hot Stocks - Newser
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Is Karyopharm Therapeutics Inc. in a long term uptrendTrade Exit Report & Real-Time Volume Surge Alerts - خودرو بانک
Strategies to average down on Karyopharm Therapeutics Inc.Weekly Trend Recap & Free Risk Controlled Daily Trade Plans - Newser
Published on: 2025-09-04 06:44:04 - Newser
Published on: 2025-09-04 06:43:46 - Newser
Can Karyopharm Therapeutics Inc. hit a new high this month2025 Bull vs Bear & Stock Market Timing Techniques - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
Will Karyopharm Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Comprehensive Market Scan Reports - خودرو بانک
What machine learning models say about Karyopharm Therapeutics Inc.Trade Exit Summary & Weekly High Potential Alerts - Newser
Is now the right time to enter Karyopharm Therapeutics Inc.Weekly Risk Report & Fast Gain Swing Alerts - خودرو بانک
How to use a screener to detect Karyopharm Therapeutics Inc. breakoutsStock Surge & Free Technical Confirmation Trade Alerts - Newser
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
What high frequency data says about Karyopharm Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
Can you recover from losses in Karyopharm Therapeutics Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - Newser
Analyzing Karyopharm Therapeutics Inc. with multi timeframe chartsQuarterly Growth Report & Accurate Trade Setup Notifications - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesBull Run & Real-Time Volume Spike Alerts - Newser
Published on: 2025-09-01 11:39:57 - beatles.ru
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):